Cynapsus reports positive top-line results from CTH-105 phase II trial of APL-130277 to treat Parkinson’s Disease
APL-130277 is the Company’s fast-acting, sublingual, thin filmstrip formulation of apomorphine. OFF episodes are a complication of Parkinson’s disease that leave patients rigid and unable to move and